No Data
No Data
What Eli Lilly, Novo Nordisk Earnings Reveal About the Future of GLP-1 Sales
Roche, Sangamo Ink Licensing Deal for Neuro Drugs
Berenberg Bank Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Raises Target Price to $339.23
J.P. Morgan Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Announces Target Price $252.09
Roche Closes Acquisition of LumiraDx's Point of Care Technology to Expand Access to Diagnostic Testing in Primary Care
Kepler Capital Maintains ROCHE HOLDINGS AG(RHHVF.US) With Buy Rating, Cuts Target Price to $320.4
No Data